Expectations for Adverum’s WetAMD Phase 1 Data in September
Insights - ADVM will present Phase 1 data in Wet AMD this September We set expectations for September data by looking at competitor RGNX Phase 1 data … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Key Takeaways From Bellus’ Chronic Cough KOL Call
Insights - Bellus hosted their Chronic Cough KOL meeting this morning. It was paneled by: Jacky Smith: lead investigator of Bellus Phase 2 trials Denis Garceau: Bellus VP of … Continue Reading
Read nowMerck’s Plan of a P2X3 Pipeline Lifts Bellus
Insights - Last week, Bellus (BLUSF) rallied from $1.50 range to over $2.00, touching a high of $2.31. This all happened on heavy volume. Remember, we first … Continue Reading
Read now
HOW GENERIC DRUGS ARE APPROVED AND WHAT THEY MEAN FOR DRUG DEVELOPERS
Education - Generic pharmaceuticals are drug products designed to be functionally identical (bioequivalent) to brand name drugs in terms of the active ingredient, dosage strengths, forms, indications, … Continue Reading
Read now
DRUG PATENTS AND EXCLUSIVITY: AN INVESTOR’S GUIDE
Education - New drugs are expensive and time-consuming to develop and market. Some studies estimate that the cost of bringing a drug to market—from R&D to FDA … Continue Reading
Read nowLate 2019 Data Could Position Gene Therapy Company As Leading Candidate in Wet AMD
Insights - Adverum (ADVM) has rallied year to date from $3.50 to $10/share as the market is picking up on the gene therapy story. With data in … Continue Reading
Premium
Acer’s Clinically Relevant Data Could Be Enough For Desperate Patient Population
Insights - Acer Therapeutics (ACER) has a PDUFA date on June 25, 2019 for the treatment of vascular Ehlers-Danlos syndrome (“vEDS”). vEDS is a serious rare disease … Continue Reading
Premium